Futibatinib: A Potent and Irreversible Inhibitor of Fibroblast Growth Factor Receptors for Treatment of the Bile Duct Cancer
- Authors: De S.1
-
Affiliations:
- Department of Chemistry, Conju-Probe
- Issue: Vol 31, No 6 (2024)
- Pages: 666-670
- Section: Anti-Infectives and Infectious Diseases
- URL: https://permmedjournal.ru/0929-8673/article/view/645170
- DOI: https://doi.org/10.2174/0929867330666230416152913
- ID: 645170
Cite item
Full Text
Abstract
Cholangiocarcinoma is a rare type of cancer. Futibatinib is an irreversible, potent, selective inhibitor of fibroblast growth factor receptors (FGFR 1-4). On September 30, 2022, the US FDA first approved futibatinib to treat adult patients with bile duct cancer whose disease is unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene mutations or other classes of rearrangements. The approval of this medicine was based on phase 3 clinical trial results including an overall response rate (ORR) of 42% and a duration of response (DoR) of 9.7 months. This short perspective summarizes Futibatinibs synthesis, physicochemical properties, dosage, route of administration, mechanism of action, binding mode, pharmacodynamics, pharmacokinetics, drug interactions, adverse events, and possible mechanism of resistance.
About the authors
Surya De
Department of Chemistry, Conju-Probe
Author for correspondence.
Email: info@benthamscience.net
References
- Bergquist, A.; von Seth, E. Epidemiology of cholangiocarcinoma. Best Pract. Res. Clin. Gastroenterol., 2015, 29(2), 221-232. doi: 10.1016/j.bpg.2015.02.003 PMID: 25966423
- Razumilava, N.; Gores, G.J. Cholangiocarcinoma. Lancet, 2014, 383(9935), 2168-2179. doi: 10.1016/S0140-6736(13)61903-0 PMID: 24581682
- Cardinale, V.; Semeraro, R.; Torrice, A.; Gatto, M.; Napoli, C.; Bragazzi, M.C.; Gentile, R.; Alvaro, D. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J. Gastrointest. Oncol., 2010, 2(11), 407-416. doi: 10.4251/wjgo.v2.i11.407 PMID: 21160904
- Liu, C.; Wang, J.; Ou, Q.J. Possible stem cell origin of human cholangiocarcinoma. World J. Gastroenterol., 2004, 10(22), 3374-3376. doi: 10.3748/wjg.v10.i22.3374 PMID: 15484322
- Khan, S.A.; Tavolari, S.; Brandi, G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int., 2019, 39(S1)(Suppl. 1), 19-31. doi: 10.1111/liv.14095 PMID: 30851228
- Lowery, M.A.; Ptashkin, R.; Jordan, E.; Berger, M.F.; Zehir, A.; Capanu, M.; Kemeny, N.E.; OReilly, E.M.; El-Dika, I.; Jarnagin, W.R.; Harding, J.J.; DAngelica, M.I.; Cercek, A.; Hechtman, J.F.; Solit, D.B.; Schultz, N.; Hyman, D.M.; Klimstra, D.S.; Saltz, L.B.; Abou-Alfa, G.K. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. Clin. Cancer Res., 2018, 24(17), 4154-4161. doi: 10.1158/1078-0432.CCR-18-0078 PMID: 29848569
- Meric-Bernstam, F.; Bahleda, R.; Hierro, C.; Sanson, M.; Bridgewater, J.; Arkenau, H.T.; Tran, B.; Kelley, R.K.; Park, J.O.; Javle, M.; He, Y.; Benhadji, K.A.; Goyal, L. Futibatinib, an irreversible fgfr14 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study. Cancer Discov., 2022, 12(2), 402-415. doi: 10.1158/2159-8290.CD-21-0697 PMID: 34551969
- Sootome, H.; Fujita, H.; Ito, K.; Ochiiwa, H.; Fujioka, Y.; Ito, K.; Miura, A.; Sagara, T.; Ito, S.; Ohsawa, H.; Otsuki, S.; Funabashi, K.; Yashiro, M.; Matsuo, K.; Yonekura, K.; Hirai, H. Futibatinib is a novel irreversible FGFR 14 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res., 2020, 80(22), 4986-4997. doi: 10.1158/0008-5472.CAN-19-2568 PMID: 32973082
- Bahleda, R.; Meric-Bernstam, F.; Goyal, L.; Tran, B.; He, Y.; Yamamiya, I.; Benhadji, K.A.; Matos, I.; Arkenau, H.T. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR14 inhibitor in patients with advanced solid tumors. Ann. Oncol., 2020, 31(10), 1405-1412. doi: 10.1016/j.annonc.2020.06.018 PMID: 32622884
- Rizzo, A.; Ricci, A.D.; Brandi, G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: Evidence to date and future perspectives. Expert Opin. Investig. Drugs, 2021, 30(4), 317-324. doi: 10.1080/13543784.2021.1837774 PMID: 33054456
- Goyal, L.; Chen, C.T.; Pierce, T.T.; Deshpande, V. Case 8-2021: A 34-year-old woman with cholangiocarcinoma. N. Engl. J. Med., 2021, 384(11), 1054-1064. doi: 10.1056/NEJMcpc2027092 PMID: 33730458
- Lee, P.C.; Hendifar, A.; Osipov, A.; Cho, M.; Li, D.; Gong, J. Targeting the fibroblast growth factor receptor (fgfr) in advanced cholangiocarcinoma: Clinical trial progress and future considerations. Cancers, 2021, 13(7), 1706. doi: 10.3390/cancers13071706 PMID: 33916849
- Doi, T.; Shitara, K.; Kojima, T.; Kuboki, Y.; Matsubara, N.; Bando, H.; Yoh, K.; Naito, Y.; Hirai, H.; Kurokawa, Y.; Kato, T.; Morizane, C. Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors. Cancer Sci., 2022, 114(2), 574-585. doi: 10.1111/cas.15486 PMID: 35838190
- Chen, L.; Zhang, Y.; Yin, L.; Cai, B.; Huang, P.; Li, X.; Liang, G. Fibroblast growth factor receptor fusions in cancer: Opportunities and challenges. J. Exp. Clin. Cancer Res., 2021, 40(1), 345. doi: 10.1186/s13046-021-02156-6 PMID: 34732230
- Duan, W.; Geng, M.; Wang, Y.; Ai, J.; Fan, J.; Dai, Y.; Ding, J. New compound having fgfr inhibitory activity and preparation and application thereof. WO2017215485A1 2017.
- Sootome, H. Therapeutic agent for fgfr inhibitor-resistant cancer WO2015008844A, 2015.
- Sagara, T.; Ito, S.; Otsuki, S.; Sootome, H. 3,5-disubstituted alkynylbenzene compound and salt thereof. US9108973B2 2013.
- Qu, L.; Chen, X.; Wei, H.; Guo, M.; Dai, S.; Jiang, L.; Li, J.; Yue, S.; Chen, Z.; Chen, Y. Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors. Commun. Chem., 2022, 5(1), 5. doi: 10.1038/s42004-021-00623-x PMID: 36697561
- Yamamiya, I.; Lester, R.; Sonnichsen, D.; Mina, M.; He, Y.; Benhadji, K.A. Effect of futibatinib on cardiac repolarization: results of a randomized, controlled, double-blind, qt/qtc, phase 1 study in healthy subjects. Clin. Pharmacol. Drug Dev., 2023, 2(3), 304-313. doi: 10.1002/cpdd.1195 PMID: 36404525
- Goyal, L.; Shi, L.; Liu, L.Y.; Fece de la Cruz, F.; Lennerz, J.K.; Raghavan, S.; Leschiner, I.; Elagina, L.; Siravegna, G.; Ng, R.W.S.; Vu, P.; Patra, K.C.; Saha, S.K.; Uppot, R.N.; Arellano, R.; Reyes, S.; Sagara, T.; Otsuki, S.; Nadres, B.; Shahzade, H.A.; Dey-Guha, I.; Fetter, I.J.; Baiev, I.; Van Seventer, E.E.; Murphy, J.E.; Ferrone, C.R.; Tanabe, K.K.; Deshpande, V.; Harding, J.J.; Yaeger, R.; Kelley, R.K.; Bardelli, A.; Iafrate, A.J.; Hahn, W.C.; Benes, C.H.; Ting, D.T.; Hirai, H.; Getz, G.; Juric, D.; Zhu, A.X.; Corcoran, R.B.; Bardeesy, N. TAS-120 overcomes resistance to atp-competitive fgfr inhibitors in patients with fgfr2 fusionpositive intrahepatic cholangiocarcinoma. Cancer Discov., 2019, 9(8), 1064-1079. doi: 10.1158/2159-8290.CD-19-0182 PMID: 31109923
- Kalyukina, M.; Yosaatmadja, Y.; Middleditch, M.J.; Patterson, A.V.; Smaill, J.B.; Squire, C.J. TAS-120 cancer target binding: Defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem, 2019, 14(4), 494-500. doi: 10.1002/cmdc.201800719 PMID: 30600916
- Lamarca, A.; Barriuso, J.; McNamara, M.G.; Valle, J.W. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J. Hepatol., 2020, 73(1), 170-185. doi: 10.1016/j.jhep.2020.03.007 PMID: 32171892
- Roskoski, R. Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol. Res., 2023, 187, 106552. doi: 10.1016/j.phrs.2022.106552 PMID: 36403719
- Vogel, A.; Segatto, O.; Stenzinger, A.; Saborowski, A. FGFR2 inhibition in cholangiocarcinoma. Annu. Rev. Med., 2023, 27(74), 293-306. doi: 10.1146/annurev-med-042921-024707 PMID: 36170665
Supplementary files
